Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Victorian Clinical Genetics Services, |
RCV002470347 | SCV002767119 | likely pathogenic | Cardiospondylocarpofacial syndrome | 2022-09-02 | criteria provided, single submitter | clinical testing | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Likely Pathogenic. Following criteria are met: 0103 - Loss of function and gain of function are known mechanisms of disease in this gene. Missense and inframe deletion variants shown to result in loss of function have been associated with cardiospondylocarpofacial (CSCF; MIM#157800) (PMID: 27426734), whereas missense variants causing gain of function have been associated with frontometaphyseal dysplasia 2 (FMD; MIM#617137) (PMID: 27426733). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from aspartic acid to asparagine. (I) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0502 - Missense variant with conflicting in silico predictions and uninformative conservation. (I) 0602 - Variant is located in a hotspot region or cluster of pathogenic variants within the catalytic domain of the serine/threonine kinase (NCBI). (SP) 0705 - No comparable missense variants have previous evidence for pathogenicity. (I) 0807 - This variant has no previous evidence of pathogenicity. (I) 0905 - No published segregation evidence has been identified for this variant. (I) 1007 - No published functional evidence has been identified for this variant. (I) 1204 - This variant has been shown to be de novo in the affected mother of this proband (parental status not tested but assumed). (SP) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign |
Center for Genomic Medicine, |
RCV002470347 | SCV004806238 | uncertain significance | Cardiospondylocarpofacial syndrome | 2024-03-25 | criteria provided, single submitter | clinical testing |